You can make a difference in the administration of intravenous immunoglobulin therapy

Journal of Infusion Nursing

Volumn 29, Issue 3 SUPPL., 2006, Pages

  Duff, Kimberly ^a  

^a NuFACTOR ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ALUMINUM MAGNESIUM HYDROXIDE; BUTALBITAL PLUS CAFFEINE PLUS PARACETAMOL; CARIMUNE NF; DESLORATADINE; DIAZEPAM; DIPHENHYDRAMINE; EXCEDRIN; FEXOFENADINE; GAMMAR P; HUMAN IMMUNOGLOBULIN; IBUPROFEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; LORATADINE; NAPROXEN; ONDANSETRON; PANGLOBULIN NF; PARACETAMOL; PETHIDINE; PROMETHAZINE; STEROID; SUMATRIPTAN SUCCINATE; TUMS; UNCLASSIFIED DRUG; VIVAGLOBIN; ZOLMITRIPTAN; IMMUNOLOGIC FACTOR;

ABORTION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANAPHYLAXIS; ANXIETY; ARTHRALGIA; ASTHMA; ATOPIC DERMATITIS; BACKACHE; BLOOD CLOTTING DISORDER; BLOOD PRESSURE VARIABILITY; BONE MARROW TRANSPLANTATION; CHILL; CHROMATOGRAPHY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC LYMPHATIC LEUKEMIA; COMBINED IMMUNODEFICIENCY; COMMON VARIABLE IMMUNODEFICIENCY; CONGESTIVE HEART FAILURE; CREUTZFELDT JAKOB DISEASE; DEEP VEIN THROMBOSIS; DEGENERATIVE DISEASE; DIABETES MELLITUS; DIURETIC THERAPY; DRUG FEVER; DRUG INDUCED HEADACHE; DYSPNEA; EBOLA VIRUS; FATAL FAMILIAL INSOMNIA; FATIGUE; FLU LIKE SYNDROME; FRACTIONATION; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; GRAFT VERSUS HOST REACTION; GUILLAIN BARRE SYNDROME; HEART INFARCTION; HEMOLYTIC ANEMIA; HEPATITIS A; HEPATITIS B; HEPATITIS C; HOME CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOREGULATION; IMMUNOTHERAPY; INFECTION; KIDNEY TUBULE NECROSIS; LUNG EMBOLISM; LUPUS VULGARIS; MIGRAINE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELOMA; NANOFILTRATION; NAUSEA; NEWBORN SEPSIS; NURSE ATTITUDE; NURSING INTERVENTION; ORGAN TRANSPLANTATION; PARVOVIRUS; PASTEURIZATION; PEMPHIGUS VULGARIS; PH; PRION DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY DISTRESS; REVIEW; RIGOR; SEVERE ACUTE RESPIRATORY SYNDROME; SIDE EFFECT; STROKE; THROAT DISEASE; URTICARIA; VOMITING; WISKOTT ALDRICH SYNDROME; X LINKED AGAMMAGLOBULINEMIA; DRUG MONITORING; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; NURSING; NURSING ASSESSMENT; PATIENT EDUCATION; PATIENT SELECTION; THROMBOCYTOPENIC PURPURA;

BONE MARROW TRANSPLANTATION; DRUG MONITORING; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; NURSE'S ROLE; NURSING ASSESSMENT; PATIENT EDUCATION; PATIENT SELECTION; PURPURA, THROMBOCYTOPENIC;

EID: 33747606698     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129804-200605001-00001     Document Type: Review

References (35)

1. Primary Immune Deficiency Diseases in America: The First National Survey of Patients and Specialists. 2003. Available at: http://www.primaryimmune.org. Accessed March 2006.
2. WHO Scientific Group. Primary immunodeficiency diseases: report of a WHO scientific group. Clin Exp Immunol. 1995;99:1-24.
3. Shearer WT, Cunninghan-Rundles C, Ochs HD. Primary immunodeficiency: looking backwards, looking forwards. J Allergy Clin Immunol. 2004;113(4):607-609.
4. Sacher RA. FRCPC, and IVIG Advisory Panel. Intravenous immunoglobulin consensus statement. J Allergy Clin Immunol. 2001;108(4):S139-S146.
5. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484-486.
6. Gelfand EW. The clinical use of intravenous immunoglobulin immunodeficiency and allergic disorders. J Intraven Nurs. 2000;23(5S):S14-S17.
7. Gelfand EW. Current status of IGIV therapy. P&T. 1996(April):4S-6S.
8. Gelfand EW. Antibody-directed therapy: past, present, and future. J Allergy Clin Immunol. 2001;108:S111-S116.
9. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve. 1999;22:1479-1497.
10. Kazatchkine MD, Kaveri S. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747-755.
11. Larroche C, Cacoub P, Soulier J, et al. Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders. Biodrugs. 2002;15:47-55.
12. Swenson MR. Autoimmunity and immunotherapy. J Intraven Nurs. 2000;23(5S):S8-S13.
13. Miller JLC, Petteway SR, Lee DC. Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma derived therapeutic proteins. J Allergy Clin Immun. 2001;108(4 Supp):S91-S94.
14. Eijkhout HW, Van den Broek PJ, Van der Meer WM. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe reactions to previous immunoglobulin therapy. Netherlands J Med. 2003:61:213-217.
15. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin on blood rheology. Lancet. 1992;339:662-664.
16. Evans-Wong LA, Davidson RJ, Stowers JM. Alterations in erythrocytes in hyperosmolar diabetic decompensation: a pathophysiological basis for impaired blood flow and for an improved design of fluid therapy. Diabetologia. 1985;28:739-742.
17. Siegal J. IVIG: Uses in neurological autoimmune diseases. Supplement to: Infusion. 2004;10(5):S1-S8.
18. Centers for Disease Control and Prevention. Renal insufficiency and failure associated with immune globulin intravenous therapy. MMWR Morb Mortal Wkly Rep. 1999;48:518-521, 1479-1497.
19. Berger M, Duff KA, Poll J, Roy S. Immunoglobulin replacement by the subcutaneous route using preparations licensed in the USA for administration by other routes. In: Dalakas MC, Spath PJ, eds. Intravenous Immunoglobulins in the Third Millenium. Proceedings of the 5th International Symposium on IGIV. New York: Parthenon; 2004:77.
20. Immune globulin intravenous (human) Polygam [product information]. Washington, DC: American Red Cross; January 2001.
21. American Red Cross. Immune globulin intravenous (human) Panglobulin NF Nanofiltered [product information]. Washington, DC: American Red Cross; February 2003.
22. Immune globulin intravenous (human) Gammagard Liquid [product information]. Deerfield, Ill: Baxter Healthcare Corporation; June 2005.
23. Immune globulin intravenous (human) Gammagard S/D [product information]. Deerfield, Ill: Baxter Healthcare Corporation; January 2001.
24. Immune globulin intravenous (Human) Iveegam EN [product information]. Deerfield, Ill: Baxter Healthcare Corporation; November 2000.
25. Immune globulin intravenous (human) Flebogamma S/D [product information]. Los Angeles, Calif: Grifols. December 2003.
26. Immune globulin intravenous (human) 5% Solvent/Detergent Treated Octagam [product information]. Centreville, Va: Octapharma; May 2004.
27. Immune globulin intravenous (human) 10% Caprylate/ Chromatography Purified Gamunex [product information]. Research Triangle Park, NC: Talecris; August 2003.
28. Immune globulin intravenous (human) Gammar - PI.V. [product information]. King of Prussia, Pa: ZLB Behring; August 2000.
29. Immune globulin intravenous (human) Carimune NF Nanofiltered [product information]. King of Prussia, Pa: ZLB Behring; February 2003.
30. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722-728.
31. Gardulf A, Andersen V, Bjorkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1996;345:365-369.
32. Gardulf A, Bjorvell H, Andersen V, et al. Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy. J Adv Nurs. 1995;21:917-927.
33. Ochs H, CE1200 Study Group. Results of the US Pivotal Trial of self-administration subcutaneous immunoglobulin replacement therapy in primary immune deficiency diseases. Abstract presented at: American Academy of Allergy, Asthma & Immunology Annual Meeting; March 5, 2006; Miami Beach, Florida.
34. Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114:936-942.
35. Phase III clinical study shows Vivaglobin, a new subcutaneous immunoglobulin, is safe and effective in treating patients with primary immunodeficiency: Study shows patients associate Vivaglobin with improved quality of life. Abstract. Available at: www.Vivaglobin.com. Accessed March 6, 2006.